Design, Synthesis, In Vitro and In Vivo Evaluation of Novel Anti-Alzheimer’s (1E,4E)-1,5-Bis[(het)aryl]penta-1,4-dien-3-one Derivatives
Géssica Oliveira Mendes, Lucas Diego Pereira Bento, Thiago Malverde de Oliveira, Deyse Brito Barbosa, Guilherme Saraiva Tsui, Ellen Nunes Gomes, Raphaela Oliveira Sales, Mateus Silva de Castro Rocha, Michel Pires da Silva, Tiago Alves de Oliveira, Eduardo Habib Bechelane Maia, Daniel Luciano Falkoski, Isabella Flores de Souza Marra, Lorena Silva Matos Andrade, Liliane Costa Vanessa Pereira Mendes, Bianca de Souza Fonseca, Lucas Matheus Gonçalves de Oliveira, Victor Diogenes Amaral da Silva, Paulo Batista de Carvalho, Alisson Marques da Silva, Alex Gutterres Taranto, Laila Cristina Moreira Damázio, Marcelo Siqueira Valle, Franco Henrique Andrade Leite · 2026
Read Design, Synthesis, In Vitro and In Vivo Evaluation of Novel Anti-Alzheimer’s (1E,4E)-1,5-Bis[(het)aryl]penta-1,4-dien-3-one Derivatives by Géssica Oliveira Mendes, Lucas Diego Pereira Bento, Thiago Malverde de Oliveira, Deyse Brito Barbosa, Guilherme Saraiva Tsui, Ellen Nunes Gomes, Raphaela Oliveira Sales, Mateus Silva de Castro Rocha, Michel Pires da Silva, Tiago Alves de Oliveira, Eduardo Habib Bechelane Maia, Daniel Luciano Falkoski, Isabella Flores de Souza Marra, Lorena Silva Matos Andrade, Liliane Costa Vanessa Pereira Mendes, Bianca de Souza Fonseca, Lucas Matheus Gonçalves de Oliveira, Victor Diogenes Amaral da Silva, Paulo Batista de Carvalho, Alisson Marques da Silva, Alex Gutterres Taranto, Laila Cristina Moreira Damázio, Marcelo Siqueira Valle, Franco Henrique Andrade Leite (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13516642.txt.
Description
Mendes and colleagues designed and tested a new family of candidate Alzheimer's disease compounds built on a curcumin-like scaffold. Their 2026 study spans synthesis, computer modeling, enzyme tests, and animal experiments. Current Alzheimer's drugs only ease symptoms, so the team targeted the two cholinesterase enzymes whose activity deepens the brain's shortage of a memory-related chemical messenger.
Mendes made the compounds through a standard condensation reaction and showed by docking simulations that they fit the active sites of both target enzymes well. Laboratory assays confirmed inhibition of both enzymes, with selected derivatives improving on the parent scaffold. In rats given a drug that mimics Alzheimer's-like damage, chosen compounds showed neuroprotective effects suggesting preserved nerve tissue. One distinct lead from a screening library expanded the chemotype's diversity, and the authors position the family as multitarget candidates needing potency and selectivity work.
Catalog record
| CREATOR | Géssica Oliveira Mendes, Lucas Diego Pereira Bento, Thiago Malverde de Oliveira, Deyse Brito Barbosa, Guilherme Saraiva Tsui, Ellen Nunes Gomes, Raphaela Oliveira Sales, Mateus Silva de Castro Rocha, Michel Pires da Silva, Tiago Alves de Oliveira, Eduardo Habib Bechelane Maia, Daniel Luciano Falkoski, Isabella Flores de Souza Marra, Lorena Silva Matos Andrade, Liliane Costa Vanessa Pereira Mendes, Bianca de Souza Fonseca, Lucas Matheus Gonçalves de Oliveira, Victor Diogenes Amaral da Silva, Paulo Batista de Carvalho, Alisson Marques da Silva, Alex Gutterres Taranto, Laila Cristina Moreira Damázio, Marcelo Siqueira Valle, Franco Henrique Andrade Leite |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 79 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |